Sponsored Links 
Gilead a Core Biotech Holding
Gilead Sciences, Inc. (GILD - Analyst Report) is a biotechnology company that develops and markets drugs for infectious diseases, including viral, fungal and bacterial infections. The company also has specialized focus on developing drugs for patients suffering from HIV/AIDS.
We remain optimistic about growth of HIV/AIDS franchise drugs Truvada and the recently approved Atripla. Earnings over the past few quarters have been above expectations, specifically on strong sales of the HIV franchise products.
We continue to be positive on the name and would recommend opportunistic buying at this level. We view the name as a core biotech to own. Our target is $52.
Read the full analyst report on GILD
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Free Stock Analysis From Zacks
Includes Zacks Long-Term Recommendation and Target Price
Loading Stories...Related Content
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Zacks FREE Registration
X Close
Loading Stories...Most Popular on Zacks.com
-1.17 %
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Feb 10, 2010 09:26 am ET |
[CLICK TO CLOSE X]